Acrivon amends 2022 equity plan, increasing share reserve to 8.6M shares.

Acrivon Therapeutics amended its 2022 Equity Incentive Plan, approved by stockholders on June 17, 2026, expanding the total share reserve to approximately 8.6 million shares including new allocations and annual increases. The plan adjustment demonstrates the company's commitment to employee retention and incentive compensation as it continues operations.